SHIFT AI Newsroom · GLOBAL
Study Highlights Postmarketing Safety Signals of GLP-1-Based Therapies
A multi-source pharmacovigilance study examines medication-use risks of GLP-1-Based Therapies in diabetes and obesity
A recent study published on Europe PMC investigated postmarketing safety signals and medication-use risks of GLP-1-Based Therapies in diabetes and obesity. The study's findings may have implications for UK healthcare professionals and patients.
What this means in the UK
The study's findings may inform UK healthcare professionals and patients about potential safety risks associated with GLP-1-Based Therapies
Known facts
- A multi-source pharmacovigilance and regulatory evidence-mapping study investigated postmarketing safety signals and medication-use risks of GLP-1-Based Therapies